Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2026 annual meeting of stockholders of Cue Biopharma, Inc. (the "Company") held on April 13, 2026 (the "Annual Meeting"), the certified results of the matters voted upon at the Annual Meeting, which are more fully described in the Company's proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission (the "SEC") on March 16, 2026, as supplemented by the proxy statement supplement filed with the SEC on March 27, 2026, are as follows (where applicable, voting results reflect fractional shares rounded down to the nearest whole share):

1. The Company's stockholders elected the following nominees to the Board of Directors of the Company (the "Board") to serve until the next annual meeting of stockholders and until their resignation or removal or their successors are duly elected and qualified, with votes cast as follows:

As previously announced in the Company's Current Report on Form 8-K filed on March 27, 2026, prior to the Annual Meeting, Usman Azam resigned as the Company's President and Chief Executive Officer and as a member of the Board, effective as of March 26, 2026. All votes cast for the election of Dr. Azam were disregarded.

2. The Company's stockholders ratified the appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with votes cast as follows:

3. The Company's stockholders approved a non-binding advisory proposal on the compensation of the Company's named executive officers, with votes cast as follows:

4. The Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's issued shares of common stock at a ratio within the range of not less than 1-for-30 and not more than 1-for-50, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of the Company's Board without further approval or authorization of the Company's stockholders, with votes cast as follows: